The majority of breast cancers (BC) (around 70%) expresses hormone receptors (HR), either estrogen (ER) or progesterone (PR) receptors or both and is responsive to endocrine therapies (ET), including aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) like fulvestrant [1]. This evidence concerns the gene NR4A1 and breast carcinoma.